An innovative solution on an emerging market…

NAOGEN PHARMA is a Nantes-based biotech created in 2016 by Jean-François CHATAL a pioneer in nuclear medicine, who has worked most of his life in this sector. In 2008, M. CHATAL founded ATLAB PHARMA, a radiopharmaceutical company, which he sold to TELIX PHARMACEUTICALS in 2018.

NAOGEN PHARMA develops, produces and commercializes innovative radiopharmaceutical solutions in non-invasive molecular imaging (PET – Positron Emission Tomography) for hospital nuclear medicine departments. The biotech develops the use of Rubidium-82 (Rb-82) in PET nuclear medicine. While this practice has already been used in the US for the past 20 years, NAOGEN PHARMA is benefitting from the emerging use of this technology in Europe.

… born along the development of the radiopharmaceutical hub of Nantes